Northwestern Mutual Wealth Management Co. Purchases 930,390 Shares of BioMarin Pharmaceutical Inc. $BMRN

Posted by Brian Himes on May 18th, 2026

Northwestern Mutual Wealth Management Co. boosted its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 3,494.9% in the 4th quarter, HoldingsChannel.com reports. The firm owned 957,011 shares of the biotechnology company’s stock after buying an additional 930,390 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in BioMarin Pharmaceutical were worth $56,875,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Activest Wealth Management bought a new stake in BioMarin Pharmaceutical during the 4th quarter worth about $26,000. Quent Capital LLC acquired a new position in shares of BioMarin Pharmaceutical during the 3rd quarter worth about $28,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of BioMarin Pharmaceutical during the 3rd quarter worth about $40,000. Smartleaf Asset Management LLC grew its position in shares of BioMarin Pharmaceutical by 92.5% during the 3rd quarter. Smartleaf Asset Management LLC now owns 749 shares of the biotechnology company’s stock worth $40,000 after buying an additional 360 shares during the period. Finally, V Square Quantitative Management LLC acquired a new position in shares of BioMarin Pharmaceutical during the 4th quarter worth about $45,000. 98.71% of the stock is owned by institutional investors.

Insider Buying and Selling

In other BioMarin Pharmaceutical news, EVP Gregory R. Friberg sold 6,326 shares of the company’s stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $60.38, for a total transaction of $381,963.88. Following the completion of the transaction, the executive vice president owned 37,578 shares of the company’s stock, valued at $2,268,959.64. This represents a 14.41% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Charles Greg Guyer sold 16,486 shares of the company’s stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $60.46, for a total value of $996,743.56. Following the transaction, the executive vice president directly owned 79,953 shares of the company’s stock, valued at approximately $4,833,958.38. This trade represents a 17.09% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 26,093 shares of company stock valued at $1,555,389. Insiders own 0.85% of the company’s stock.

BioMarin Pharmaceutical Stock Performance

NASDAQ:BMRN opened at $51.81 on Monday. BioMarin Pharmaceutical Inc. has a twelve month low of $50.76 and a twelve month high of $66.28. The company has a quick ratio of 4.20, a current ratio of 5.81 and a debt-to-equity ratio of 0.23. The business has a 50 day moving average price of $55.48 and a two-hundred day moving average price of $56.31. The company has a market cap of $10.01 billion, a P/E ratio of 37.82, a price-to-earnings-growth ratio of 0.39 and a beta of 0.23.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Oppenheimer decreased their target price on BioMarin Pharmaceutical from $98.00 to $95.00 and set an “outperform” rating for the company in a research report on Tuesday, February 24th. Stifel Nicolaus set a $68.00 target price on BioMarin Pharmaceutical in a research report on Tuesday, February 24th. Loop Capital set a $105.00 target price on BioMarin Pharmaceutical in a research report on Monday, March 2nd. Weiss Ratings lowered BioMarin Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday. Finally, Canaccord Genuity Group boosted their price objective on BioMarin Pharmaceutical from $104.00 to $116.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, BioMarin Pharmaceutical presently has an average rating of “Moderate Buy” and an average price target of $89.91.

Check Out Our Latest Analysis on BioMarin Pharmaceutical

BioMarin Pharmaceutical Company Profile

(Free Report)

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.